Tyrothricin

Summary

Tyrothricin (CHEMBL577736) is an approved protein (ATC S01AA05); indicated across 1 condition including eye infectious disorder.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Protein
• ATC class: S01AA05 (+2 more)
• Indications: 1 condition
• Chemistry: 1228.4 Da · C65H85N11O13

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL577736
Name	Tyrothricin
Type	Protein
Max phase	4
FDA approved	no
PubChem CID	452550
ATC	S01AA05, R02AB02, D06AX08
Molecular formula	C65H85N11O13
Molecular weight	1228.4
InChIKey	NLJVXZFCYKWXLH-DXTIXLATSA-N

SMILES: CC(C)C[C@H]1C(=O)N[C@@H](C(=O)N2CCC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](C(=O)[C@@H](NC(=O)[C@@H](N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N1)CCCN)C(C)C)CC3=CC=C(C=C3)O)CCC(=O)O)CC(=O)N)CC4=CC=CC=C4)CC5=CC=CC=C5)CC6=CC=CC=C6

IUPAC name: 3-[(3R,6S,9S,12S,15S,17S,20S,22R,25S,28S)-20-(2-amino-2-oxoethyl)-9-(3-aminopropyl)-3,22,25-tribenzyl-15-[(4-hydroxyphenyl)methyl]-6-(2-methylpropyl)-2,5,8,11,14,18,21,24,27-nonaoxo-12-propan-2-yl-1,4,7,10,13,16,19,23,26-nonazabicyclo[26.3.0]hentriacontan-17-yl]propanoic acid

Also known as: Bactratycin, Coltirot, Dermotricine, Hydrotricine, Martricin, NSC-757363, Solutricine, Tirotricina, Tyri 10, Tyroderm, Tyrosur, Tyrothricin

Patent coverage: 440 distinct patent families (922 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

1 approved indication. FDA phase 4, plus an anticancer drug’s labelled cancer uses (which ChEMBL often logs at phase 3).

Indication	Phase	MONDO	EFO
eye infectious disorder	4	MONDO:0043885	EFO:1001888

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).